Abstract 3180
Background
Hepatic stone or lithiasis is a known risk factor for intrahepatic cholangiocarcinoma (ICC) in clinic, however the process and genomic background of the hepatobiliary lithiasis associated cholangiocarcinoma (BCAC) is completely unknown.
Methods
Here, we retrospectively collected 81 paired intrahepatic cholangiocarcinoma (ICC) frozen cancerous and adjacent tissues including those patients combining biliary calculi. Whole exome sequence (WES, average 400x) and RNA-seq were applied to characterize this cohort.
Results
Among them, prognosis of 64 patients from 2011 to 2013 revealed that BCAC had poor overall survival (18.6 months vs 28.6 months, P = 0.024, Kaplan-Meier) compared to those of non-stone ICC. WES of 81 ICC patients showed that BCAC displayed a distinct mutation pattern, with EPHA2 and SMAD4 genes significantly enriched in BCAC (P < 0.05, Fisher exact test) and epigenetic regulators IDH1, BAP1 and calcium channel RYR1 more enriched in non-calculi ICCs. Transcriptome profile showed that BCAC was different from canonical ICCs. Gene set enrichment analysis revealed that RESPONSE_TO_LIPID and CALCIUM_ION_BINDING were among the top significant changed gene sets, which might play important roles in BCACs.
Conclusions
Our results demonstrate that BCAC is a distinct CCAs subtype and biliary calculi might be an independent factor for ICC and result in a poor prognosis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
BGI-Shenzhen.
Funding
Shenzhen Science and Technology Innovation Committee.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3392 - Post-hoc analysis of the nintedanib exposure-response relationships in the CHIVA trial in advanced ovarian cancer: (a GINECO study)
Presenter: Skerdi HAVIARI
Session: Poster Display session 2
Resources:
Abstract
714 - The feasibility and efficacy of gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian insufficiency in patient with malignant ovarian germ cell tumors
Presenter: Min Kyu Kim
Session: Poster Display session 2
Resources:
Abstract
1753 - Ex vivo cytotoxicity and in vivo antitumor activity of a novel highly selective STAT3 inhibitor YHO-1701 for ovarian and endometrial cancer
Presenter: Kosei Hasegawa
Session: Poster Display session 2
Resources:
Abstract
3739 - Mutational landscapes and tumor mutational burden expression in endometrial cancer
Presenter: Yingli Zhang
Session: Poster Display session 2
Resources:
Abstract
2109 - Clinical features and frequency of mismatch repair protein deficiency in ovarian clear cell and endometrioid carcinoma patients.
Presenter: Kazuhiro Takehara
Session: Poster Display session 2
Resources:
Abstract
4554 - Prospective study evaluating white adipose tissue inflammation and clinicopathologic features in endometrial cancer
Presenter: Lea Moukarzel
Session: Poster Display session 2
Resources:
Abstract
3645 - Cancer-specific survival with or without adjuvant chemotherapy in high-risk stage I endometrial cancer
Presenter: Jenny Ko
Session: Poster Display session 2
Resources:
Abstract
3394 - Pembrolizumab in Patients with MSI-H Advanced Endometrial Cancer from the KEYNOTE-158 Study
Presenter: David Omalley
Session: Poster Display session 2
Resources:
Abstract
3388 - Who drops out of cervical cancer screening? Results from the EDIFICE 6 survey
Presenter: Thibault de La Motte Rouge
Session: Poster Display session 2
Resources:
Abstract
2485 - Identification of a RNA-Seq Based Signature to Improve Prognostic for Uterine Sarcoma
Presenter: Jian-Guo Zhou
Session: Poster Display session 2
Resources:
Abstract